"Medical leader" Novartis Shanghai or 150 layoffs
-
Last Update: 2019-11-19
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
(November 19, 2019) expand RNAi therapy for mass diseases and reach a cooperation between Novo Nordisk and Novo Nordisk; the first domestic "recombinant human coagulation factor Ⅷ" is listed on the market; the first-line efficacy of opdivo single choice liver cancer is comparable to that of sorafenib; see the huge "appetite" of MS Market from the perspective of the 45% increase in the sales of Merck cladribine tablets It wasn't just the sales people who were laid off First! O medicine will be reported again Isn't it a bad thing? Is it a good thing? Appetite is not small Only return to the essence of medical treatment and balance the relationship between medical treatment and commercial operation They do what they want RNAi treatment model is gradually used to treat more patients with public diseases The R & D expenses of 101 pharmaceutical companies were exposed.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
